Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor pathway in hypertension

Current Hypertension Reports

Volumn 15, Issue 1, 2013, Pages 31-38

  Fraga Silva, Rodrigo Araujo ^a,c   Ferreira, Anderson Jose ^a,b   Dos Santos, Robson Augusto Souza ^a,b  

^a National Institute of Science and Technology in Nanobiopharmaceutics   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c EPFL   (Switzerland)

Author keywords

Angiotensin converting enzyme 2; Angiotensin (1 7); Hypertension; Mas receptor; RAS; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALISKIREN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7] MAS RECEPTOR; CANDESARTAN; CGEN 856; CGN 857; CYCLODEXTRIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; CYCLIZATION; DRUG FORMULATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TARGETING; ENZYME ACTIVATION; HEART PROTECTION; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOTENSIN I; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM;

EID: 84872602247     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0324-1     Document Type: Review

References (83)

1. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(2A):3A-9. discussion 10A.
2. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439-65.
3. Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens. 1998;12(5):295-9. (Pubitemid 28274359)
4. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med. 2002;113(5):409-18. (Pubitemid 35230007)
5. Ma TK, et al. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273-92.
6. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol. 1997;59:395-412. (Pubitemid 27142448)
7. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens. 2000;13(1 Pt 2):31S-8.
8. de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52(3):415-72.
9. Vickers C, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838-43. (Pubitemid 34952556)
10. Tipnis SR, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):33238-43.
11. Donoghue M, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1-9.
12. Santos RA, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100(14):8258-63. (Pubitemid 36842532)
13. Zisman LS, et al. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation. 2003;108(14):1679-81. (Pubitemid 37243653)
14. Ferrario CM, et al. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30(3 Pt 2):535-41. (Pubitemid 27444228)
15. Ferreira AJ, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55(2):207-13.
16. Ferreira AJ, et al. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens. 2012;2012:147825.
17. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol. 2009;302(2):193-202.
18. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res. 2005;38(4):499-507. (Pubitemid 40703878)
19. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93(5):519-27. (Pubitemid 351595060)
20. Kokubu T, et al. Purification and properties of angiotensin I-converting enzyme in human lung and its role on the metabolism of vasoactive peptides in pulmonary circulation. Adv Exp Med Biol. 1979;120B:467-75.
21. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res. 2002;35(9):1001-15. (Pubitemid 35452880)
22. Steckelings UM, Unger T. Angiotensin II type 2 receptor agonists-where should they be applied? Expert Opin Investig Drugs. 2012;21(6):763-6.
23. Widdop RE, et al. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40(4):516-20.
24. Savoia C, et al. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20(2):125-32.
25. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224-36.
26. Bosnyak S, et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond). 2011;121(7):297-303.
27. Albiston AL, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001;276(52):48623-6.
28. Chai SY, et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci. 2004;61(21):2728-37. (Pubitemid 40022434)
29. Schiavone MT, et al. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 1988;85(11):4095-8.
30. Rice GI, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(Pt 1):45-51. (Pubitemid 39389449)
31. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27(3 Pt 2):523-8. (Pubitemid 26086221)
32. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol. 2003;284(6):H1985-94.
33. Freeman EJ, et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 1996;28(1):104-8. (Pubitemid 26231097)
34. Gava E, et al. Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. Regul Pept. 2012;175(1-3):30-42.
35. Xu P, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008;51(2):574-80. (Pubitemid 351156450)
36. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res. 2011;34(2):154-60.
37. Fraga-Silva RA, et al. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med. 2008;14(1-2):28-35. (Pubitemid 351356883)
38. •• Fraga-Silva RA, et al. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo). 2011;66(5):837-41. This work shows that the oral formulations Ang-(1-7)-CyD produces biological activity through increasing Ang-(1-7) plasma level and in a Mas-dependent manner.
39. Fraga-Silva RA, et al. The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb Haemost. 2012;108(6). doi: 10.1160/TH12-06-0396.
40. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000;91(1-3):45-62.
41. Silva DM, et al. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides. 2007;28(3):702-7. (Pubitemid 46204993)
42. •• Verano-Braga T, et al. Time-resolved quantitative phosphoproteomics: new insights into angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res. 2012;11(6):3370-81. This study provides new concepts and new understanding of the Ang-(1-7) signal transduction, shedding light on the mechanisms underlying Mas activation.
43. Heitsch H, et al. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension. 2001;37(1):72-6. (Pubitemid 32064242)
44. Sampaio WO, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49(1):185-92. (Pubitemid 46360359)
45. Sampaio WO, et al. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50(6):1093-8. (Pubitemid 350172931)
46. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24(50):7410-25. (Pubitemid 41637981)
47. Zhao Y, Wang Y, Zhu WG. Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol. 2011;3(5):276-82.
48. Brunet A, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96(6):857-68. (Pubitemid 29165088)
49. Zhu Z, et al. Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction. J Cardiovasc Pharmacol. 2002;40(5):693-700. (Pubitemid 36109287)
50. Giani JF, et al. Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol. 2008;93(5):570-8. (Pubitemid 351595049)
51. Mercure C, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res. 2008;103(11):1319-26.
52. Gomes ER, et al. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway. Hypertension. 2010;55(1):153-60.
53. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31(1 Pt 2):356-61.
54. Iyer SN, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31(2):699-705. (Pubitemid 28086958)
55. Collister JP, Hendel MD. The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst. 2003;4(3):176-9. (Pubitemid 37419854)
56. Kucharewicz I, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension. 2002;40(5):774-9. (Pubitemid 35278618)
57. Yamada K, et al. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension. 1998;32(3):496-502. (Pubitemid 28429139)
58. Wiemer G, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002;40(6):847-52. (Pubitemid 35434905)
59. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev. 2006;24(3-4):239-46. (Pubitemid 46435006)
60. da Costa-Goncalves AC, et al. AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection. Exp Physiol. 2012. doi: 10.1113/expphysiol.2012.068551.
61. Pinheiro SV, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004;44(4):490-6. (Pubitemid 39281501)
62. Lemos VS, et al. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol. 2005;46(3):274-9. (Pubitemid 41262828)
63. Ferreira AJ, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1113-9.
64. Ferreira AJ, et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci. 2007;81(11):916-23. (Pubitemid 47374211)
65. Benter IF, et al. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 2006;290(2):H684-91.
66. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension. 2005;46(4):948-52.
67. Carvalho MB, et al. Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension. 2007;50(4):762-7. (Pubitemid 47442743)
68. Singh Y, Singh K, Sharma PL. Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. Mol Cell Biochem. 2012. doi: 10.1007/s11010-012-1489-2.
69. Shemesh R, et al. Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem. 2008;283(50):34643-9.
70. • Savergnini SQ, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010;56(1):112-20. This recent study was the first indicating that the novel Mas agonist, CGEN-856S, might have a therapeutic value, since it induces vasorelaxation, antihypertensive, and cardioprotective effects.
71. Lula I, et al. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides. 2007;28(11):2199-210. (Pubitemid 47610792)
72. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo). 2004;52(8):900-15. (Pubitemid 41701863)
73. •• Marques FD, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011;57(3):477-83. This work is the first showing the cardioprotective effects of Ang-(1-7) formulation, Ang-(1-7)-CyD.
74. • Kluskens LD, et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther. 2009;328(3):849-54. In this work it was developed the cyclized Ang-(1-7) compound which was proposed as an excellent method to render more resistance against proteolytic breakdown but preserving its activity.
75. Durik M, et al. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int J Hypertens. 2012;2012:536426.
76. Hernandez Prada JA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51(5):1312-7. (Pubitemid 351555943)
77. Ferreira AJ, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011;96(3):287-94.
78. Ferreira AJ, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(11):1048-54.
79. Fraga-Silva RA, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010;16(5-6):210-5.
80. Murca TM, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept. 2012;177(1-3):107-15.
81. Murca TM, et al. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp Physiol. 2012;97(6):699-709.
82. Sasaki S, et al. Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension. 2001;38(1):90-4. (Pubitemid 34224777)
83. Davie AP, McMurray JJ. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension. 1999;34(3):457-60. (Pubitemid 29426763)